CAR Treg cell therapy for recent-onset type 1 diabetes
Part of Hormones & metabolism, Immune system & allergy clinical trials.
This trial tests a new treatment using your own immune cells (called Tregs) that are modified to target and calm the immune attack on the pancreas. It is for people diagnosed with stage 3 type 1 diabetes within the last 12 to 24 months who still make some insulin.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 35 years old.
- You have been diagnosed with stage 3 type 1 diabetes within the last 12 to 24 months and still make some insulin (measurable by a blood test after a mixed meal).
- You have at least one type 1 diabetes-related antibody (other than insulin antibodies).
- You are willing to have a continuous glucose monitor (CGM) for study visits and follow intensive diabetes management.
- You are fully vaccinated for your age and have no active infections or serious medical conditions like heart disease or cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a one-time cell treatment (CARC-101C) for people recently diagnosed with type 1 diabetes. The goal is to see if it is safe and can help preserve the body's ability to make some insulin.
This early-stage trial tests a new type of immune cell therapy (CAR-T cells) designed to stop the body's immune system from attacking insulin-producing cells in type 1 diabetes. The goal is to help preserve remaining pancreas function in people with early-stage disease.
This trial tests whether giving your own regulatory T cells (a type of immune cell) back to you can help slow or stop the immune attack on your pancreas in type 1 diabetes. It is for people aged 8 to 65 who still make some insulin.
This trial tests a new combination treatment for children who have been diagnosed with stage 1 type 1 diabetes, meaning they have some markers but do not yet need insulin. The treatment uses special immune cells (Treg cells) and an antibody (anti-CD20) to try to preserve the body's ability to make insulin.
This trial tests a new gene therapy that uses your own blood stem cells to treat type 1 diabetes soon after diagnosis. It aims to see if this treatment can help preserve your body's ability to make insulin.
This trial tests a new type of immune therapy called CAR T-cells that target two markers on your B cells (CD19 and BCMA). It is for people with certain autoimmune diseases that have not improved or have come back after standard treatments. The goal is to see if this therapy can help control the disease.
Hear when a new Stage 3 Type 1 Diabetes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.